In addition to the potent anticancer efficacy in preclinical patient-derived models of AML upon treatment with AGS67E, it was reported for the first time that CD37 is highly expressed in T-cell lymphomas and AML, thus allowing the exploration of the possibility of using the antigen as a target in these clinical settings [136]. Here, CD37 is linked to acute myeloid leukemia.